Proxima

Executive Summary

Proxima is a Cambridge-based biotechnology company pioneering the use of artificial intelligence and machine learning to decode and design protein interactions. Founded in 2018, the company aims to unlock a new chapter in medicine by making protein interactions programmable, thereby creating proximity-based therapeutics. Proxima operates an integrated discovery platform that combines AI, structural proteomics, and proximity modulation, enabling the rational design of molecules that can bring proteins into close proximity to modulate cellular functions. While the company is privately held and has not disclosed funding or pipeline details, its focus on AI-driven protein engineering positions it at the forefront of the growing proximity-based drug development field, which includes targeted protein degradation and other modalities. The company's location in Cambridge, a major biotech hub, and its reliance on cutting-edge computational approaches suggest potential for significant impact, though it remains at an early stage with no publicly announced products or partnerships.

Upcoming Catalysts (preview)

• 2026Potential Series A or B Funding Round70% success
• 2026Publication of Preclinical Data in Peer-Reviewed Journal50% success
• 2027Announcement of Strategic Partnership with Pharma Company40% success